aiTBS for Relieving NSSI in Depressive Patients

Accelerated Intermittent Theta Burst Stimulation for the Treatment of Non-suicidal Self-injury in Patients With Unipolar Depression and Bipolar Depression: a Sham-controlled Study

Repetitive transcranial magnetic stimulation (rTMS) has been successfully used to help patients with treatment resistant depression. However, its role in alleviating self injuries without suicidal ideation remained uncertain. This trial will compare the effectiveness of active accelerated intermittent theta burst stimulation (aiTBS) rTMS to a placebo control on non-suicidal self injury (NSSI) in patients with unipolar disorder and bipolar disorder.

Study Overview

• Status: Recruiting
• Conditions: Bipolar Depression; Major Depressive Disorder
• Intervention / Treatment: Device: Active iTBS; Device: Sham iTBS

Detailed Description

The study will evaluate the efficacy and safety of aiTBS in unipolar and bipolar depressive patients with NSSI or suicidal thoughts and behaviors by measuring changes in clinical ratings at baseline, after all the treatments, and 2 weeks, 4 weeks after treatment. 60 inpatients will be randomized to receive active or sham interventions administered to the left dorso-lateral prefrontal cortex. The treatment will apply active aiTBS rTMS involving 1800 pulses (9 minutes), 5x daily at 60 minutes intervals for 5 days. Changes in mood and sleep from baseline to the end of the study will be measured with The Hamilton Rating Scale for Depression-17 item (HAM-D17), Hamilton Anxiety Scale (HAMA), Young's Mania Scale (YMRS), and Pittsburgh Sleep Quality Index (PSQI) . Non-suicidal self injury will be assessed by the Deliberate Self-Harm Inventory (DSHI) and the Ottawa self-injury inventory (OSI). Suicidal ideation and behaviors assessments include Beck Suicidal Scale Inventory (BSI), the Ottawa self-injury inventory (OSI) and several questions from Self-Injurious Thoughts and Behaviors Interview - Revised (SITBI-R). Improvement of cognitive dysfunction could be measured by Barratt Impulsiveness Scale-11 (BIS-11), near infrared spectroscopy (fNIRS). Treatment Emergent Symptom Scale (TESS) would be used to eliminate side effects of combined drugs at baseline and the adverse event record form (AERF) will be used to appraise the safety of aiTBS treatment using these parameters. To record the change in sensitivity to pain and examine the tolerability of the treatment for these participants, visual analogue scale (VAS) is employed after completing 5 sessions treatment every day.

• Study Type: Interventional
• Enrollment (Estimated): 60
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Renrong Wu, M.D. Ph.D; Phone Number: +8615874179855; Email: wurenrong@csu.edu.cn
• Study Contact Backup: Name: Jing Huang, M.D.; Email: jinghuangserena001@csu.edu.cn

Study Locations

• China
  • Hunan
    • Changsha, Hunan, China, 410011
      • Recruiting
      • Mental Health Institute of Second Xiangya Hospital,CSU
      • Contact: Renrong Wu, PhD, M.D; Phone Number: 15874179855; Email: wurenrong2013@163.com
      • Contact: Jing Huang, MD; Email: jinghuangserena001@csu.edu.cn

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 12 years to 18 years (Child, Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Documentation of DSM-5 criteria for current major depressive disorder (MDD) or bipolar disorder (BD) will be required for study entry.
2. Ages between 12 and 18 years
3. At least 1 caregivers to supervise the patient within 3 month.
4. A score of greater than 17 on the HAM-D17.
5. Occurrences of self injury behavior consistent with the DSM-5 criteria of NSSI more than 3 times in a month.
6. Willingness to participate in the study and sign informed consents

Exclusion Criteria:

1. Substance abusers such as psychoactive drugs or alcohol.
2. Severe physical disability and unable to complete follow-up.
3. Comorbid other major mental illnesses that meet the DSM-5 criteria, such as schizophrenia, mental retardation, dementia, severe cognitive impairment, attention deficit hyperactivity disorder, etc.
4. Currently in a manic episode, YMRS>12; rapid-cycling bipolar disorder, bipolar disorder with mixed features.
5. Suffering from any severe physical disease, neurological disease, traumatic brain injury, etc, that affects the structure or function of the brain in the lifetime.
6. Unable to read, understand and complete the assessment or to cooperate with the investigators.
7. Any implants covering a pacemaker, metallic or magnetic objects in the body, or other conditions not suitable for rTMS.
8. A history or family history of epilepsy and other contraindications to TMS.
9. Daily use of benzodiazepines (more than 2mg/d), theophylline, stimulants such as methylphenidate, anticonvulsants, bupropion, etc.
10. Those who have received systematic psychotherapy (interpersonal relationship therapy, dynamic therapy, cognitive behavioral therapy) within 3 months before baseline.
11. Other examination abnormalities considered to be inappropriate by investigators.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: active stimulation; Active Intermittent theta burst stimulation to the dorsolateral prefrontal cortex; 5 sessions per day, for 5 days.	Device: Active iTBS; MagPro X100
Sham Comparator: Sham stimulation; Sham stimulation to the dorsolateral prefrontal cortex; 5 sessions per day, for 5 days.	Device: Sham iTBS; MagPro X100

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Changes in the Deliberate Self-Harm Inventory (DSHI)	Containing one subscale ranging from 0 to 57 to measure the frequencies of NSSI behavior and one subscale ranging from 0 to 76 to measure the severity of NSSI behavior.	Baseline, after 5 treatment days, 2 week and 4 week post-treatment

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Changes in number of occurrences of Non-Suicidal Self Injurious ideation Through SITBI-R	The frequency of NSSI thoughts during the latest week	Baseline, after 5 treatment days, 2 week and 4 week post-treatment
Changes in likelihood of future Non-Suicidal Self Injury Through SITBI-R	Range from 0-4, higher score indicates more likelihood to conduct NSSI in the future	Baseline, after 5 treatment days, 2 week and 4 week post-treatment
Changes in the 17-item Hamilton Rating Scale for Depression (HAMD-17)	This will be measured as both a continuous variable (scores on HAMD-17 ) and a categorical one (i.e. the response rates of >50% reduction from baseline HAMD-17 and remission rates defined as HAMD-17 <7).	Baseline, after 5 treatment days, 2 week and 4 week post-treatment
Changes in Pittsburgh Sleep Quality Index (PSQI)	Range from 0-21, higher score indicates severe poorer sleep quality	Baseline, after 5 treatment days, 2 week and 4 week post-treatment
Changes in Hamilton Anxiety Scale (HAMA)	Range from 0-56, higher score indicates more severe symptoms	Baseline, after 5 treatment days, 2 week and 4 week post-treatment
Changes in Young's Mania Scale (YMRS)	Range from 0-60, higher score indicates more severe symptoms	Baseline, after 5 treatment days, 2 week and 4 week post-treatment
Changes in the subscale of addiction of NSSI from OSI (Ottawa self-injury inventory)	Range from 0- 28, higher score indicates higher addiction.	Baseline, after 5 treatment days, 2 week and 4 week post-treatment
Changes in Barratt Impulsiveness Scale-11 (BIS-11)	Range from 26-104, higher score indicates higher impulsivity	Baseline, after 5 treatment days, 2 week and 4 week post-treatment
Changes in cerebral blood flow of PFC through Near Infrared Spectroscopy (fNIRS)	Measuring the hemoglobin concentration of cerebral cortex during resting state and verbal fluency test.	Baseline, after 5 treatment days
Changes in Beck Suicidal Scale Inventory (BSI)	Range from 0- 38, higher score indicates more severe suicide ideation.	Baseline, after 5 treatment days, 2 week and 4 week post-treatment
Changes in The Clinical Global Impression (CGI)	Measuring the symptom severity, overall improvement, and therapeutic response to intervention.	Baseline, after 5 treatment days, 2 week and 4 week post-treatment
Changes in the Deliberate Self-Harm Inventory-ideation (DSHI-ideation)	Range from 0 to 57 to measure the frequency of NSSI ideation	Baseline, after 5 treatment days, 2 week and 4 week post-treatment

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
The retrospect of NSSI behavior	Measured by Ottawa self-injury inventory (OSI), including reasons, addiction, site of NSSI, etc.	Baseline
Borderline features of patients with NSSI	Measured by The Borderline Personality Feature Scale for Children - 11 (BPFS-C-11) ranging from 24 to 120	Baseline
Fundelmental parental style of caregivers of patients with NSSI	Measured by the Parental Bonding Instrument (PBI) containing two subscales ranging from 0 to 75 for both mother and father version.	Baseline
Safety and tolerance of the intervention	Recording any side effects in the adverse event record form (AERF).	After 5 treatment days
Child maltreatment of patients with NSSI	Measured by the Childhood Trauma Questionnaire (CTQ) ranging from 25 to 125.	Baseline

Collaborators and Investigators

• Sponsor: Central South University

Study record dates

Study Major Dates

• Study Start (Actual): July 1, 2022
• Primary Completion (Estimated): February 28, 2025
• Study Completion (Estimated): February 28, 2025

Study Registration Dates

• First Submitted: May 13, 2022
• First Submitted That Met QC Criteria: May 19, 2022
• First Posted (Actual): May 20, 2022

Study Record Updates

• Last Update Posted (Estimated): April 25, 2024
• Last Update Submitted That Met QC Criteria: April 24, 2024
• Last Verified: April 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Behavioral Symptoms; Mental Disorders; Mood Disorders; Bipolar and Related Disorders; Depression; Depressive Disorder; Bipolar Disorder; Depressive Disorder, Major
• Other Study ID Numbers: TMS20220425

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No